德賽西威(002920.SZ):2024年研發投入達到21.92億元,佔銷售額的7.94%
格隆匯6月16日丨德賽西威(002920.SZ)在互動平臺表示,公司始終將自主研發與創新能力作爲核心競爭力,長期堅持高水平的研發投入,以確保持續的技術引領和行業領先地位。2024年,公司研發投入達到21.92億元,佔銷售額的7.94%。公司已與奇瑞汽車達成相關合作,共同開發艙駕一體中央計算平臺,該平臺基於公司自主研發的智能中央計算平臺ICPS01E打造,採用創新的單芯片多域融合解決方案,成爲業內首款可量產艙駕一體SOC產品,標誌着公司在智能駕駛核心技術領域取得重大突破。同時,公司已與昊鉑簽訂戰略合作協議,將基於新一代高算力芯片共同研發推動新一代艙駕一體乃至中央計算平臺的加速落地,適配L4高級別自動駕駛軟硬件系統需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.